ABVX Abivax SA
Financings ·
Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results.
Abivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027.
Abivax SA is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with an initial focus on inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Its lead drug candidate, obefazimod, is designed to enhance expression of the microRNA miR-124, which the company describes as a natural regulator of the inflammatory response. Obefazimod is in Phase 3 clinical development for moderately to severely active ulcerative colitis. The company initiated a Phase 2b clinical trial in patients with Crohn's disease in the fourth quarter of 2024. Abivax is also evaluating potential combination therapy opportunities in IBD, and it reports preclinical combination data with etrasimod in a mouse model of IBD. It is strengthening its development portfolio with follow-on compounds based on its miR-124 platform and by assessing external early drug candidates in IBD. The company was incorporated as a société anonyme under the laws of France on December 4, 2013. Its shares trade on Euronext Paris and its ADSs are listed on the Nasdaq Global Market.
| Product or program | What it is | Stage |
|---|---|---|
| Obefazimod (ulcerative colitis) | miR-124 enhancer for moderately to severely active ulcerative colitis | Phase 3 |
| Obefazimod (Crohn's disease) | miR-124 enhancer for Crohn's disease | Phase 2b |
| miR-124 follow-on compounds | New candidates generated from the miR-124 enhancer library |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | €177.8 million | €146.5 million |
| Net income (loss) | -€336.1 million | -€176.2 million |
| Cash from operations | -€161.1 million | -€154.1 million |
| Cash and equivalents | €516.7 million | €144.2 million |
| Short-term investments | €21.4 million | €7.6 million |
Our latest story on this, dated Jun 30, 2026: "Abivax launches $600,000,000 offering of American Depositary Shares". The story links the filing or release it is based on. Read the story.
Abivax SA trades under the ticker ABVX on EURONEXT.
Abivax SA is listed on EURONEXT. Our directory also records these other listings: DUS:2X1; FWB:2X1; GETTEX:2X1; HAM:2X1; HAN:2X1; LS:A14UQC; LSE:0RA9; LSX:A14UQC; MUN:2X1; NASDAQ:ABVX; SWB:2X1; TRADEGATE:2X1; VIE:ABVX; XETR:2X1.
The SEC Central Index Key (CIK) for Abivax SA is 1956827. Its filings are on SEC EDGAR.
78,536,412 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-03-23.
Our directory records Abivax SA under France.
Our directory classifies Abivax SA as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Abivax SA is FR0012333284.
aibio.space lists Abivax SA among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as I0.
Abivax SA is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases, with an initial focus on inflammatory bowel diseases, including ulcerative colitis and Crohn's disease. Its lead drug candidate, obefazimod, is designed to enhance expression of the microRNA miR-124, which the company describes as a natural regulator of the inflammatory response.
Obefazimod (ulcerative colitis): miR-124 enhancer for moderately to severely active ulcerative colitis Stage: Phase 3.
Obefazimod (Crohn's disease): miR-124 enhancer for Crohn's disease Stage: Phase 2b.
Our latest story on Abivax SA, dated Jun 30, 2026: "Abivax launches $600,000,000 offering of American Depositary Shares". Abivax's preliminary supplement of June 30, 2026 described a $600,000,000 offering. The final supplement priced 6,400,000 ADSs at $125.0000 each, $800,000,000 in all, one day after the company announced Phase 3 maintenance results. Source.
From our story of Jun 30, 2026: The repurchase, agreed May 4, 2026, cost $90.0 million, $45.0 million in cash and $45.0 million in shares. Source.
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 424B7. Source
Reported a financing. SEC Form 6-K. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 6-K. Source
Filed a final prospectus for a securities offering. SEC Form F-3ASR. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form F-3. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio